Monte Rosa Therapeutics (GLUE) Profit After Tax: 2023-2025
Historic Profit After Tax for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$27.1 million.
- Monte Rosa Therapeutics' Profit After Tax fell 13.50% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 117.54%. This contributed to the annual value of -$72.7 million for FY2024, which is 46.31% up from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Profit After Tax is -$27.1 million, which was down 120.26% from -$12.3 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Profit After Tax's 5-year high stood at $46.9 million during Q1 2025, with a 5-year trough of -$35.2 million in Q2 2023.
- In the last 3 years, Monte Rosa Therapeutics' Profit After Tax had a median value of -$30.3 million in 2024 and averaged -$18.2 million.
- Data for Monte Rosa Therapeutics' Profit After Tax shows a peak YoY increase of 246.66% (in 2025) and a maximum YoY decrease of 13.50% (in 2025) over the last 5 years.
- Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Profit After Tax stood at -$33.3 million in 2023, then surged by 140.35% to $13.4 million in 2024, then declined by 13.50% to -$27.1 million in 2025.
- Its Profit After Tax was -$27.1 million in Q3 2025, compared to -$12.3 million in Q2 2025 and $46.9 million in Q1 2025.